On December 2-3, the 2022 China Health Industry Innovation Summit and the 4th "CHIP Award" award ceremony was held in Shanghai and the "CHIP Seed List" was announced. Hopstem's iPSC cell therapy product development platform project won the "2022 Drug Innovation CHIP Seed TOP10".
The projects of companies on the list need to address unmet clinical needs, have original and differentiated innovations, and have bright prospects for commercialization. Since the launch of the first "CHIP Seeds" list, it has received widespread attention and positive responses from people in the health industry across the country. After rigorous screening by the review team, Hopstem was honored to be on the list. It reflects the medical and health industry's high recognition of Hopstem's development potential in the field of pharmaceutical innovation and iPSC cell therapy product development platform.
Hopstem Wins the Third Prize of VB-Link Competition
Huayi List: Hopstem Ranks Top 10 Most Promising Biotech Companies
The iPSC-derived Human Forebrain Neural Progenitor Cell Injection hNPC01 of Hopstem has Received CDE's Clinical Implication Approval
The launch meeting of the clinical research project of Hopstem hNPC01 universal cell therapy product for the treatment of stroke sequelae was successfully held.
R&D Center: 3rd Floor, Building 16, No.260 6th Street,
Economic and Technological Development Area,
Hangzhou, Zhejiang, China
Manufacturing Center: 3rd & 4th Floor, Building 10,
Hexiang Technology Center, Qiantang New Area,
Hangzhou, Zhejiang, China
U.S. Office: 103 Carnegie center, Suite 300, Princeton,
NJ 08540, USA
